Welcome to our dedicated page for Inhibikase Therapeutics SEC filings (Ticker: IKT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Inhibikase Therapeutics, Inc. (Nasdaq: IKT) SEC filings page on Stock Titan provides access to the company’s publicly filed regulatory documents, including current reports on Form 8-K and other submissions made through the U.S. Securities and Exchange Commission’s EDGAR system. As a clinical-stage pharmaceutical company developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary disease, Inhibikase uses these filings to report material corporate events, financing transactions, governance matters, and key developments in its pulmonary arterial hypertension (PAH) program.
Inhibikase’s recent 8-K filings describe, among other items, the entry into an underwriting agreement for a public offering of common stock and pre-funded warrants, the expected net proceeds from that offering, and amendments to outstanding warrants in connection with plans to advance IKT-001 to a global pivotal Phase 3 study in PAH. Other 8-Ks report financial results for specific periods, updates to corporate presentations, and outcomes of the company’s annual meeting of stockholders, including director elections, auditor ratification, and equity incentive plan amendments.
Through this page, users can review how Inhibikase discloses its clinical development strategy for IKT-001, including the planned two-part adaptive Phase 3 IMPROVE-PAH study, as well as its capital-raising activities that support ongoing research and development. Stock Titan enhances these filings with AI-powered summaries that explain the core points of lengthy documents such as current reports, shelf registration statements, and related exhibits. Investors can also monitor information related to equity offerings, warrant terms, and other securities matters that may affect the company’s capital structure.
By consolidating Inhibikase’s SEC filings and applying AI-driven analysis, this page helps readers quickly understand the regulatory and financial context surrounding the company’s PAH-focused clinical programs and broader corporate activities.
Sands Capital Life Sciences Pulse Fund II, L.P. and related entities report a 10.8% beneficial stake in Inhibikase Therapeutics, Inc. They collectively hold 13,018,965 shares of common stock, based on 120,899,650 shares outstanding as of November 20, 2025, as referenced in the issuer's prospectus supplement.
The filing explains that this ownership is attributed to Sands Capital Life Sciences Pulse Fund II, its investment manager Sands Capital Alternatives, LLC, and Frank M. Sands, who has ultimate voting and investment power. It also describes additional Series A-1 and Series B-1 warrants held by the fund that are not counted as beneficially owned because they are not exercisable within 60 days and are subject to a 19.99% ownership cap after exercise.
Inhibikase Therapeutics, Inc. reported a new stock option grant to its Chief Executive Officer and director, Mark T. Iwicki. On January 5, 2026, he was awarded a stock option covering 4,982,706 shares of common stock at an exercise price of $2.01 per share.
The option is described as a right to buy common stock and had no purchase price at grant. It becomes exercisable in 36 equal monthly installments starting on January 5, 2026, and each vesting installment depends on his continued employment through that vesting date. The option relates to 4,982,706 underlying common shares and is scheduled to expire on January 5, 2036, if not exercised earlier.
Inhibikase Therapeutics reported that President & Head of R&D Cabell Christopher received a grant of stock options on January 5, 2026. The award covers 900,117 stock options, each with an exercise price of $2.01 per share, giving the right to buy common stock. According to the disclosure, the options vest in 36 equal monthly installments starting January 5, 2026, and vesting is conditioned on Christopher’s continued employment through each vesting date. Following this grant, Christopher beneficially holds 900,117 derivative securities directly.
Inhibikase Therapeutics reported an insider equity award for its Chief Financial Officer, David McIntyre. He received a stock option grant covering 986,319 shares of common stock at an exercise price of $2.01 per share on January 5, 2026. The option was granted at a cost of $0 on the grant date, so no shares were bought or sold in this transaction.
The option vests and becomes exercisable in 36 equal monthly installments starting on January 5, 2026, and is scheduled to expire on January 5, 2036. Following this grant, McIntyre beneficially owns derivative securities representing 986,319 option rights held directly.
Sands Capital Life Sciences Pulse Fund II, L.P. filed a Form 4 reporting a purchase of 2,068,965 shares of Inhibikase Therapeutics, Inc. (IKT) common stock in an underwritten public offering on 11/21/2025 at $1.45 per share. Following this transaction, the fund reports holding 13,018,965 shares directly.
The filing is made jointly by related entities, including Sands Capital Alternatives, LLC and affiliates, with the reporting persons identified as a director and 10% owner of IKT. Footnotes explain that additional Series A-1 and Series B-1 warrants to purchase 5,475,000 and 10,068,120 shares of common stock, respectively, are not included in the reported beneficial ownership because they are not exercisable within 60 days and are subject to a 19.99% beneficial ownership cap.
Inhibikase Therapeutics announced an underwritten public offering of 46,091,739 shares of common stock and pre-funded warrants to purchase up to 22,873,779 additional shares. Each share is priced at $1.45 and each pre-funded warrant at $1.449, with an exercise price of $0.001 per share. The company granted underwriters a 30-day option to buy up to 10,344,827 more shares at the public offering price, less underwriting discounts and commissions.
Inhibikase expects net proceeds of approximately $93.6 million, or $107.7 million if the underwriters’ option is fully exercised. The pre-funded warrants are immediately exercisable and include ownership caps generally at 4.99% or 9.99%, adjustable up to 19.99% with notice. The company also amended outstanding Series A-1 and Series B-1 warrants issued in 2024 to reflect its plan to advance IKT-001 to a global pivotal Phase 3 trial in pulmonary arterial hypertension.
Inhibikase Therapeutics, Inc. is conducting a primary offering of 46,091,739 shares of common stock and pre-funded warrants to purchase up to 22,873,779 shares of common stock at $1.45 and $1.449, respectively. The deal is expected to generate gross proceeds of about $99,997,127, with approximately $93.6 million in net proceeds after underwriting fees and expenses. The company plans to use the cash, together with existing funds, mainly to advance its lead PAH candidate IKT-001 through an adaptive Phase 3 program and for broader R&D, potential acquisitions, and general corporate purposes, which it estimates will fund operations into 2029.
Inhibikase Therapeutics has filed a prospectus supplement for a public offering of common stock and, for some investors, pre-funded warrants that are exercisable for common shares at an exercise price of $0.001 per share and do not expire, subject to ownership limits. The warrants are not expected to trade on an exchange.
The company is a clinical-stage pharma focused on cardiopulmonary disease, with lead candidate IKT-001, an oral prodrug of imatinib mesylate for pulmonary arterial hypertension (PAH). IKT-001 has shown bioequivalence to imatinib doses used in prior PAH studies, and the FDA has indicated the 505(b)(2) pathway is appropriate. An adaptive Phase 3 trial in PAH, IMPROVE-PAH, is expected to start in the first quarter of 2026.
As of September 30, 2025, Inhibikase had 74,807,911 common shares outstanding and $77.3 million in cash, cash equivalents and marketable securities. The company previously raised approximately $110 million in an October 2024 private placement to support IKT-001 and holds U.S. patent protection for IKT-001 into 2033, with possible method-of-use protection to 2044. Net proceeds from this offering are expected to fund IKT-001 development, other R&D, possible acquisitions and general corporate purposes, but will cause dilution to new investors. In connection with this deal, the existing ATM prospectus under the $300 million shelf registration has been terminated, though the related sales agreement remains in effect.
Inhibikase Therapeutics plans to advance its drug candidate IKT-001 directly into a global pivotal Phase 3 trial for pulmonary arterial hypertension (PAH). The Phase 3 IMPROVE-PAH study is expected to start in the first quarter of 2026 and use a two-part adaptive design. Part A will be a double-blind, placebo-controlled study in 140 patients with a primary endpoint of pulmonary vascular resistance at Week 24, while Part B will use the same format in 346 patients with a primary endpoint of six-minute walk distance at Week 24. The company believes this design offers advantages such as dose titration to the highest tolerable dose, uninterrupted enrollment, and potential sample size re-estimation. Inhibikase also terminated its at-the-market sales agreement prospectus with Jefferies, having made no stock sales under it, although the underlying sales agreement remains in effect.
Inhibikase Therapeutics (IKT) reported a larger quarterly loss as it advanced PAH development and integrated an asset acquisition. For Q3 ended September 30, 2025, net loss was $11.93 million, driven by higher research and development expense of $7.65 million and selling, general and administrative expense of $5.61 million. Year-to-date net loss reached $35.52 million.
Liquidity remained solid, with cash, cash equivalents and marketable securities totaling about $77.3 million as of September 30, 2025. Operating cash outflow for the nine months was $20.27 million. The CorHepta acquisition was accounted for as an asset acquisition; the Company expensed acquired IPR&D of $7.36 million and recorded a contingent consideration liability of $2.42 million. IKT entered a global license for risvodetinib, receiving $1 upfront and eligibility for up to $47.5 million in milestones plus double‑digit royalties. An at‑the‑market sales agreement with Jefferies for up to $200 million was established; no sales occurred by quarter end.